ENDPOINTS NEWS5d
Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers
Merck and Daiichi Sankyo have passed a Phase 3 with the lead antibody-drug conjugate from the megadeal they disclosed at last ...
Investing11d
AstraZeneca duy trì chỉ tiêu cổ phiếu, vượt trội so với xếp hạng sau sự kiện nhà đầu tư
Hợp tác với Daiichi Sankyo, datopotamab deruxtecan của AstraZeneca cho thấy xu hướng cải thiện tỷ lệ sống sót tổng thể trong thử nghiệm Giai đoạn III cho một số bệnh nhân ung thư phổi. Hơn nữa, SOPHiA ...
chiaki12d
Top 10 Kem dưỡng trắng da ban đêm tốt nhất từ các “brand” nổi tiếng
Transino được biết đến là một thương hiệu dược mỹ phẩm thuộc công ty Daiichi Sankyo Healthcare - là một trong những công ty con của tập đoàn Daiichi Sankyo. Các sản phẩm của thương hiệu nổi tiếng này ...
Reuters5d
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Yahoo Finance5d
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd (OTC:DSNKY) and being jointly developed ...
MarketWatch5d
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...
AOL5d
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their ...
FiercePharma4d
Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
In interviews with Fierce Pharma Marketing at Fierce’s annual Digital Pharma East event in Philadelphia last week, marketing leaders from Bayer, Daiichi Sankyo and argenx discussed that slower ...
Yahoo Finance22d
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease
2,3 Patient comorbidities and frailty may unnecessarily affect CVD management. 4,5,6 Daiichi Sankyo remains committed to its promise to continue expanding medical knowledge to support better CV ...
Nasdaq14d
Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial
(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ongoing IDeate-Lung01 Phase 2 trial shows ifinatamab ...
Morningstar18d
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO
Data at WCLC and ESMO showcasing Daiichi Sankyo’s progress towards its goal of creating new standards of care for patients with cancer will include six late-breaking presentations, including two ...
Business Wire22d
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...